Biogen Inc. — Drug Manufacturers - General. Scored on the same transparent model behind the daily rankings.
★
BIIB
Biogen Inc. · Drug Manufacturers - General
FCF$2.4bB
Rev+1.2%C
D/E0.44B
P/E36.7xC+
PEG5.09D
32.2Score
$206.63$30.5B
1Y Target$235.32Analyst consensus · 31 analysts
5Y Target$344.53Compound horizon
10Y Target$511.08Long-dated conviction
FCF$2.4bTTMB
FCF $2.4b — solid, comfortably covers operations and capital return
Rev+1.2%TTM YoYC
Revenue +1.2% — flat, mature phase or headwinds present
D/E0.44B
D/E 0.44 — near the Healthcare debt median (≈60th pctile)
P/E36.7xC+
P/E 36.7 — above the Healthcare median (≈75th pctile)
PEG5.09D
PEG 5.09 — very expensive; pricing in best-case scenarios
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 32.2
Quality0.61
Growth0.20
Value0.27
Entry · Margin of safety
52-week rangeNear 52-week high
6% off the 12-month high
vs DCF fair value46% belowest. fair value ~$385
What the price assumes: free cash flow compounding at ~-1% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability25% · Bgross profit ÷ total assets (Novy-Marx)
ROIC7.8% · C+return on invested capital — not score-weighted
Why now
Drug Manufacturers - General · market cap $30.5b. 6% off the 52-week high of $219.72. 31 sell-side analysts rate this a Buy with a mean 1-yr target of $235.32 (implying +14% upside).
Moat
Net margin 14% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
Horizon
1-3 yr $235.32 (31-analyst consensus) — fundamentals + valuation re-rating. 5 yr $344.53 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $511.08 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
BIIB vs the Top Picks average
Pillar
BIIB
Book avg
Diff
Quality
0.61
0.84
-0.23
Growth
0.20
0.92
-0.72
Value
0.27
0.75
-0.48
Averaged across the 30 names in today's Top Picks (mean score 82.6). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · BIIB
Trend
-15.8 over 36 daily scores
From 48.0 (Jun 22) → 32.2 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · BIIB
$
%
%
Shares to buy
9
Position size
$1,860
3.7% of portfolio
Stop price
$154.97
25% below $206.63
$ at risk if stopped
$464.92
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Biogen Inc. (BIIB): score, valuation & FAQ
Biogen Inc. (BIIB) is a Drug Manufacturers - General company that scores 32.2 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
The model flags PEG (D) as weaker areas. On valuation, BIIB sits about 46% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -1% annual free-cash-flow growth over the next decade.
Is BIIB a good stock to buy?
Bull Rankings scores BIIB 32.2 out of 100 on its quality-growth model, which is a weak reading. A score is a quantitative screen of Biogen Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does BIIB score 32.2 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). BIIB grades middle-of-pack across the strip, and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is BIIB overvalued or undervalued?
Based on $206.63, BIIB sits about 46% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -1% annual free-cash-flow growth over the next decade. It trades at a 36.7x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in BIIB?
Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.